Rebecca H. Buckley

Duke University — United States

Immunology and Microbiology · Life Sciences

79h-index23.7kcitations379works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunodeficiency and Autoimmune Disorders(231), Immune Cell Function and Interaction(57), Cytomegalovirus and herpesvirus research(50), Hematopoietic Stem Cell Transplantation(48), Blood disorders and treatments(47)

Publications379 total

Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC
Blood Advances·2025Open Access
T-cell Exhaustion In Patients With Severe Combined Immunodeficiency Transplanted Without Conditioning OR Graft Versus Host Disease Prophylaxis
Journal of Allergy and Clinical Immunology·2025
The Role of Second Hematopoietic Cell Transplantation (HCT2) in Patients with Severe Combined Immunodeficiency (SCID): A Report from the Primary Immune Deficiency Treatment Consortium (PIDTC)
Transplantation and Cellular Therapy·2025
Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency
Journal of Clinical Immunology·2024· 7 citedOpen Access
106 Outcomes Following Hematopoietic Cell Transplant for CD3δ Severe Combined Immune Deficiency: a PIDTC Natural History Study
Clinical Immunology·2024
Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia
Clinical Immunology·2024· 5 citedOpen Access
Outcomes Following Matched Sibling Donor Transplant for Severe Combined Immunodeficiency: A Report from the Pidtc
Transplantation and Cellular Therapy·2024· 3 cited
Improving Compliance with State-Recommended Guidelines for Severe Combined Immunodeficiency (SCID) Newborn Screening (NBS) in the Intensive Care Nursery (ICN)
Journal of Allergy and Clinical Immunology·2024Open Access
Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study
Journal of Allergy and Clinical Immunology·2023· 14 citedOpen Access
Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium
The Lancet·2023· 93 citedOpen Access
Safety and Efficacy of Hizentra® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies
Journal of Clinical Immunology·2023Open Access
Racial and Ethnic Disparities in Outcomes following Hematopoietic Stem Cell Transplant (HCT) in Patients with Severe Combined Immunodeficiency (SCID)
Clinical Immunology·2023
Early immune reconstitution in an infant with adenosine deaminase deficient severe combined immunodeficiency started on enzyme replacement therapy
Clinical Immunology·2023
Newborn screening has improved the survival of infants with severe combined immunodeficiency (SCID) – a Primary Immune Deficiency Treatment Consortium (PIDTC) study
Clinical Immunology·2023· 2 cited
A Single-Center Review of Severe Combined Immune Deficiency (SCID) Newborn Screening (NBS) Data in the Neonatal Intensive Care Unit (NICU)
Journal of Allergy and Clinical Immunology·2023Open Access
Event Free Survival in Severe Combined Immune Deficiency (SCID) Infants after Conditioned Umbilical Cord Blood Transplantation (UCBT) Benefits from Omitting Serotherapy
Transplantation and Cellular Therapy·2023Open Access
Abstract 1335: Natural history of biomarker changes associated with gut inflammatory disease in postnatal human development
Journal of Biological Chemistry·2023Open Access
The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions
Journal of Allergy and Clinical Immunology·2022· 107 citedOpen Access
The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions
Journal of Allergy and Clinical Immunology·2022· 36 citedOpen Access
Safety and Efficacy of Hizentra ® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies
2022Open Access
page 1 of 19Next →

Frequent Co-authors

Jennifer M. Puck(10), Luigi D. Notarangelo(9), William T. Shearer(7), Donald B. Kohn(7), Hans D. Ochs(6), M. Louise Markert(6), Linda M. Griffith(6), Thomas A. Fleisher(6), Morton J. Cowan(6), Richard J. O’Reilly(6), Mary Ellen Conley(6), Harry L. Malech(5), Joseph L. Roberts(5), Sung‐Yun Pai(5), Brent R. Logan(5), Christopher C. Dvorak(5), Kathleen E. Sullivan(5), Trudy N. Small(5), Roberta Parrott(4), Neena Kapoor(4)